Retatrutide vs Semaglutide
Compare Retatrutide, Semaglutide: half-life, time to Cmax, dosing interval, published dose ranges and titration — citation-backed, research use only.
| RetatrutideLY3437943View Retatrutide → | SemaglutideOzempic, Wegovy, RybelsusView Semaglutide → | |
|---|---|---|
| Class | GLP-1 | GLP-1 |
| Route | Subcutaneous | Subcutaneous |
| Plasma half-life | ~6.0 days (144 h) | ~6.9 days (165 h) |
| Time to Cmax | 36 h | 24 h |
| Typical interval | Once weekly | Once weekly |
| Published dose range | 2–12 mg | 0.25–2.4 mg |
| Titration ladder | 2 → 4 → 6 → 8 → 12 mg | 0.25 → 0.5 → 1 → 1.7 → 2.4 mg |
| Summary | Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only. | Long-acting GLP-1 receptor agonist. Once-weekly subcutaneous. Titration over 16 weeks reduces GI side effects. |
Source references
Retatrutide
- Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023)
- Rosenstock J et al., Lancet 402:529 (titration arms) (2023)
Semaglutide
- FDA Wegovy USPI — half-life ~1 week (165 h) (2024)
- STEP 1 trial — NEJM 384:989 (titration schedule) (2021)
- Hall S et al., Clin Pharmacokinet 57:1571 (Cmax ~24 h SC) (2018)
For research use only. Not for human consumption. This tracker visualises only the doses you have logged or scheduled — it does not recommend dose sizes, does not suggest what to take, and is not pharmacokinetically calibrated. It is not medical advice and does not diagnose, treat, cure, or prevent any condition. Consult a licensed clinician before making any medical decision.